Pharma Focus Asia
KP - Choose our fully recyclable blister films

Personalized Cancer Monitoring Technology Launched to Treat Cancer Patients

A Personalized Cancer Monitoring (PCM) technology designed for minimally invasive monitoring and recurrence surveillance for early-stage cancer has been launched by ArcherDX.

This new technology is designed to provide clinicians in a range of healthcare settings with access to important genomic information that can help them deliver care to patients both quickly and more cost-effectively.

It should particularly help community hospitals and laboratories for which this kind of data is typically unavailable.

ArcherDX has an ongoing collaboration with a research study being conducted by Cancer Research UK called Tracking Cancer Evolution through therapy (Rx), known as TRACERx.

Professor Charles Swanton, Group Leader, University College London (UCL), and the Francis Crick Institute and Dr. Christopher Abbosh, Principal Clinical Fellow at UCL, who are part of the investigation are using ArcherDX's technology to detect low-volume minimal residue disease at high levels of sensitivity.

Such information and advances in detecting and monitoring cancer will help TRACERx researchers reach the goal of a more personalized approach to develop cancer treatments.

Latest Issue
Get instant
access to our latest e-book
THERMOFISHER SEACertara - Is your drug program on trackMasterControl - Manufacturing demoMasterControl - QMS demoThermo Fisher Scientific - Rapid Mycoplasma TestingThermoFisher Scientific - Save costs on your downstream process todayThermo Fisher Scientific - PeptonesMerck - Mobius® products5th Annual Pharma Manufacturing and Automation Convention 2023DUPHAT 202410TH ANNUAL GCC PHARMACY CONGRESS 202314th Annual Emirates Cardiac Society Conference 2023The International Hand & Wrist Congress 2023LabAsia 2023Pharma & Patient USA 2023Pharma Customer Engagement Europe 2023CHEMICAL INDONESIA 2024INALAB 2024